HCW Biologics (HCWB) Price & Analysis

Compare

189 Followers

HCWB Stock Chart & Stats

$3.99

-$0.02(-4.12%)

At close: Jan 08 4:00 PM EST

$3.99

-$0.02(-4.12%)

Day’s Range― - ―

52-Week Range$1.84 - $41.26

Previous CloseN/A

Volume102.01K

Average Volume (3M)103.58K

Market Cap

$5.40M

Enterprise Value$14.77M

Total Cash (Recent Filing)$1.10M

Total Debt (Recent Filing)$7.50M

Price to Earnings (P/E)―

Beta1.20

Next Earnings

Apr 01, 2026

EPS Estimate

-1.77

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-4.13

Shares Outstanding2,701,607

10 Day Avg. Volume28,978

30 Day Avg. Volume103,577

Financial Highlights & Ratios

PEG Ratio-2.31

Price to Book (P/B)-102.22

Price to Sales (P/S)269.62

P/FCF Ratio-47.76

Enterprise Value/Market Cap2.73

Enterprise Value/Revenue34.99

Enterprise Value/Gross Profit-164.98

Enterprise Value/Ebitda-1.69

Forecast

1Y Price Target

$35.00

Price Target Upside777.19% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-2.52

Revenue Forecast (FY)$7.00M

Bulls Say, Bears Say

Bulls Say

Analyst RecommendationAnalyst recommendation for HCW Biologics Inc. is a 'Buy'.

Clinical DevelopmentHCW Biologics Inc. has selected a next-generation checkpoint candidate for clinical development.

Preclinical Study ResultsPreclinical studies of HCW11-040 have demonstrated an outperformance vs. pembrolizumab monotherapy in immune-cell activation and expansion, enhancement of immune-cell infiltration into the tumors, and immune-cell cytotoxicity against cancer cells.

Bears Say

Financial CommunicationHCW Biologics has received further communication from WY Biotech that it is not likely to meet the amended payment deadline.

HCW Biologics News

HCW Biologics enters $4M warrant inducement

HCW Biologics (HCWB) entered into a warrant inducement agreement with an investor for the immediate exercise of certain...

23d ago

HCWB

HCW Biologics announces initiation of FIH trial of HW9302

HCW Biologics (HCWB) announced the first patient was dosed at The Ohio State University Wexner Medical Center for...

24d ago

HCWB

HCW Biologics Secures $4M Through Warrant Exercise

The latest update is out from HCW Biologics ( ($HCWB) ). On November 19, 2025, HCW Biologics Inc....

22d ago

HCWB

HCW Biologics Amends License Agreement with Trimmune

An announcement from HCW Biologics ( ($HCWB) ) is now available. On November 17, 2025, HCW Biologics Inc....

23d ago

HCWB

HCW Biologics Begins Phase 1 Trial for HCW9302

The latest update is out from HCW Biologics ( ($HCWB) ). On November 18, 2025, HCW Biologics announced...

24d ago

HCWB

HCW Biologics announces latest update for tetra-valent ICI Program

HCW Biologics (HCWB) announced the latest updated data for its tetra-valent, second-generation pembrolizumab-based Immune Checkpoint Inhibitor, ICI, Program...

1M ago

HCWB

HCW Biologics announces data presented for TCE Program based on TRBC platform

HCW Biologics (HCWB) announced the data presented for their tetra-valent, second-generation T-Cell Engager, TCE, Program based on their...

1M ago

HCWB

HCW Biologics Advances Alopecia Areata Treatment with Phase 1 Study of HCW9302

Hcw Biologics, Inc. (($HCWB)) announced an update on their ongoing clinical study. Study Overview: HCW Biologics, Inc. is...

2M ago

HCWB

HCW Biologics participates in virtual investor ‘What This Means’ segment

HCW Biologics (HCWB) announced that Peter Rhode, PhD, Chief Scientific Officer and Vice President of Clinical Operations of...

2M ago

HCWB

HCW Biologics Granted Nasdaq Compliance Extension

HCW Biologics ( ($HCWB) ) just unveiled an announcement. On August 19, 2025, HCW Biologics Inc. received notice...

2M ago

HCWB

HCW Biologics congratulates Wugen on equity financing

HCW Biologics (HCWB) congratulates Wugen on its recently announced $115M equity financing led by Fidelity Management & Research...

3M ago

HCWB

HCW Biologics’ Innovative Lead Candidate HCW11-040 Boosts Cancer Therapy Potential

Analyst Michael Okunewitch of Maxim Group maintained a Buy rating on HCW Biologics, retaining the price target of...

3M ago

HCWB

HCW Biologics announces results from second-gen T-cell engager programs

HCW Biologics (HCWB) announced that its scientists have successfully developed second-generation, tissue factor-targeting T-cell engagers against solid tumors,...

3M ago

HCWB

HCW Biologics Extends License Fee Payment Deadline

HCW Biologics ( ($HCWB) ) has issued an announcement. HCW Biologics Inc. and WY Biotech Co., Ltd. have...

3M ago

HCWB

HCWB FAQ

What was Hcw Biologics, Inc.’s price range in the past 12 months?

Hcw Biologics, Inc. lowest stock price was $1.84 and its highest was $41.26 in the past 12 months.

What is Hcw Biologics, Inc.’s market cap?

Hcw Biologics, Inc.’s market cap is $5.40M.

When is Hcw Biologics, Inc.’s upcoming earnings report date?

Hcw Biologics, Inc.’s upcoming earnings report date is Apr 01, 2026 which is in 110 days.

How were Hcw Biologics, Inc.’s earnings last quarter?

Hcw Biologics, Inc. released its earnings results on Nov 14, 2025. The company reported -$4.13 earnings per share for the quarter, missing the consensus estimate of $1.58 by -$5.71.

Is Hcw Biologics, Inc. overvalued?

According to Wall Street analysts Hcw Biologics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Hcw Biologics, Inc. pay dividends?

Hcw Biologics, Inc. does not currently pay dividends.

What is Hcw Biologics, Inc.’s EPS estimate?

Hcw Biologics, Inc.’s EPS estimate is -1.77.

How many shares outstanding does Hcw Biologics, Inc. have?

Hcw Biologics, Inc. has 2,701,607 shares outstanding.

What happened to Hcw Biologics, Inc.’s price movement after its last earnings report?

Hcw Biologics, Inc. reported an EPS of -$4.13 in its last earnings report, missing expectations of $1.58. Following the earnings report the stock price went up 2%.

Which hedge fund is a major shareholder of Hcw Biologics, Inc.?

Currently, no hedge funds are holding shares in HCWB

Company Description

Hcw Biologics, Inc.

HCW Biologics (HCWB) is a biotechnology company focused on the development and commercialization of innovative therapies for various diseases, particularly those related to cancer and immune disorders. The company specializes in biologics, utilizing advanced technologies to create targeted treatments that harness the body's immune system to fight diseases. HCWB operates in the healthcare sector with a commitment to improving patient outcomes through its cutting-edge research and development efforts.

HCW Biologics (HCWB) Earnings & Revenues

Historic Earnings Reports

HCWB Stock 12 Month Forecast

Average Price Target

$35.00

▲(777.19% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","9":"$9","18":"$18","27":"$27","36":"$36"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$35.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$35.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$35.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,9,18,27,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.97,4.510769230769231,7.0515384615384615,9.592307692307694,12.133076923076924,14.673846153846155,17.214615384615385,19.755384615384614,22.296153846153846,24.836923076923078,27.377692307692307,29.91846153846154,32.45923076923077,{"y":35,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.97,4.510769230769231,7.0515384615384615,9.592307692307694,12.133076923076924,14.673846153846155,17.214615384615385,19.755384615384614,22.296153846153846,24.836923076923078,27.377692307692307,29.91846153846154,32.45923076923077,{"y":35,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.97,4.510769230769231,7.0515384615384615,9.592307692307694,12.133076923076924,14.673846153846155,17.214615384615385,19.755384615384614,22.296153846153846,24.836923076923078,27.377692307692307,29.91846153846154,32.45923076923077,{"y":35,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":26,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.2,"date":1730419200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":17.84,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":11.13,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":11.24,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.73,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.21,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.75,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.12,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.35,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.82,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.87,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.97,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >